Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | NQO1 | P15559 | 1/20 | 0.32 |
| ▸ | BACE1 | P56817 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.31 |
| ▸ | DRD3 | P35462 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | TYR | P14679 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7116131 | 0.76 | TSHR (0.43) | CYP3A4TDP1HPGD | |
| SCHEMBL2513778 | 0.71 | ACHE (0.48) | SLC28A3ACHENQO1BACE1MEN1 | |
| SCHEMBL12599519 | 0.68 | SLC28A3 (0.44) | SLC28A3ACHENQO1BACE1MEN1 | |
| SCHEMBL16046757 | 0.68 | SLC28A3 (0.56) | SLC28A3ACHENQO1BACE1MEN1 | |
| SCHEMBL2979293 | 0.67 | SLC28A3 (0.50) | SLC28A3ACHENQO1BACE1MEN1 | |
| SCHEMBL11512131 | 0.67 | EGFR (0.58) | SLC28A3MEN1KMT2ATDP1HPGD | |
| SCHEMBL11512368 | 0.64 | MAPT (0.59) | MEN1KMT2ATDP1 | |
| SCHEMBL4082314 | 0.64 | SLC28A3 (0.41) | SLC28A3ACHENQO1BACE1MEN1 | |
| SCHEMBL544300 | 0.64 | CYP3A4 (0.46) | SLC28A3NQO1BACE1MEN1CYP3A4 | |
| SCHEMBL7495620 | 0.64 | SLC28A3 (0.41) | SLC28A3ACHENQO1BACE1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10301346-B2 | Nucleotide analogues | QIAGEN SCIENCES, LLC (US) | 2019-05-28 | — | — | US | disclosed |
| US-20170130051-A1 | NUCLEOTIDE ANALOGUES | IsoPlexis Corporation | 2017-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170130051-A1 | NUCLEOTIDE ANALOGUES | NT5C3B, SAMHD1, DUT | SLC28A3 1608/4885ACHE 2506/4885NQO1 734/4885 |
| US-10301346-B2 | Nucleotide analogues | NT5C3B, SAMHD1, DUT | SLC28A3 1608/4885ACHE 2506/4885NQO1 734/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.